Published in Drug Week, May 6th, 2005
"Few studies have addressed the incidence of graft-versus-host disease (GVHD) or survival after ABO-incompatible allogeneic peripheral blood stem cell transplantation (PBSCT). We analyzed the clinical outcome of ABO incompatibility after allogeneic PBSCT.
"A total of 89 consecutive adult patients with hematological diseases including 49 ABO-identical, 20 major, 15 minor, and 5 bidirectional ABO-incompatible transplants were enrolled from four medical centers in Korea," researchers in South Korea report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.